<?xml version="1.0" encoding="utf-8"?>
<?xml-stylesheet type='text/xsl' href='../../ld2webpage.xsl'?>
<LOBBYINGDISCLOSURE2>
  <imported>Y</imported>
  <pages>8</pages>
  <submitURL>
  </submitURL>
  <organizationName>Novartis</organizationName>
  <prefix>
  </prefix>
  <firstName>
  </firstName>
  <lastName>
  </lastName>
  <registrantDifferentAddress>N</registrantDifferentAddress>
  <address1>701 PENNSYLVANIA AVENUE, NW, #725</address1>
  <address2>
  </address2>
  <city>WASHINGTON</city>
  <state>DC</state>
  <zip>20004</zip>
  <zipext>
  </zipext>
  <country>USA</country>
  <principal_city>
  </principal_city>
  <principal_state>
  </principal_state>
  <principal_zip>
  </principal_zip>
  <principal_zipext>
  </principal_zipext>
  <principal_country>
  </principal_country>
  <contactIntlPhone>
  </contactIntlPhone>
  <selfSelect>Y</selfSelect>
  <clientName>Novartis</clientName>
  <clientGovtEntity>N</clientGovtEntity>
  <senateID>9204-12</senateID>
  <houseID>335890000</houseID>
  <reportYear>2016</reportYear>
  <reportType>1A</reportType>
  <terminationDate>
  </terminationDate>
  <noLobbying>
  </noLobbying>
  <income>
  </income>
  <expenses>3093000.00</expenses>
  <expensesMethod>A</expensesMethod>
  <printedName>Daniel Casserly</printedName>
  <signedDate>4/20/2016 2:04:13 PM</signedDate>
  <alis>
    <ali_info>
      <issueAreaCode>HCR</issueAreaCode>
      <specific_issues>
        <description>S.2041 - Promoting Life-Saving New Therapies for Neonates Act of 2015 
S.481 - Improving Regulatory Transparency for New Medical Therapies Act
H.R.2841 - Fair Access for Safe and Timely Generics Act of 2015
H.R.6 - 21st Century Cures Act
Gene Therapy
Personalized Medicine
Section 9008 of Patient Protection and Affordable Care Act
FSA/HSA - Support reinstating coverage of OTC products
HR351/S351 - Medicine Decisions Act of 2011 (IPAB)
340B Drug Discount Program
Dual Eligibles Program
DQSA Implementation (Track &amp; Trace)
Certified Importer Program
MDUFA (Medical Device User Fee Act) Implementation
Drug Importation
Reimbursement for medical devices
GMP related to manufacturing sites
Biosimilars
PDUFA
Low-income Subsidy in Part D
REMS
FCLCA
Value of Medicines
Drug Cost/Pricing
Biosimilars Reimbursement
Generic Drugs
Medicaid
FDA Regulations of Lab Developed Tests (LDT)
Reimbursement for LDTs
2015 Omnibus Appropriations bill
Part B Demo
Regrow Act
IPAB
Generic Drug Labeling
H.R.4784 Lower Drug Costs through Competition Act
S.2615 Increasing Competition in Pharmaceuticals Act </description>
      </specific_issues>
      <federal_agencies>U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Food &amp; Drug Administration (FDA), White House Office, Centers For Medicare and Medicaid Services (CMS), Office of Management &amp; Budget (OMB)</federal_agencies>
      <lobbyists>
        <lobbyist>
          <lobbyistFirstName>Daniel</lobbyistFirstName>
          <lobbyistLastName>Casserly</lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>Shawn</lobbyistFirstName>
          <lobbyistLastName>O'Neail</lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>Jason</lobbyistFirstName>
          <lobbyistLastName>Van Pelt</lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>Leo</lobbyistFirstName>
          <lobbyistLastName>Farber</lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>Sarah</lobbyistFirstName>
          <lobbyistLastName>Haller</lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>Wendy</lobbyistFirstName>
          <lobbyistLastName>Sussman</lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>Candie</lobbyistFirstName>
          <lobbyistLastName>Phipps</lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>
          </lobbyistFirstName>
          <lobbyistLastName>
          </lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>
          </lobbyistFirstName>
          <lobbyistLastName>
          </lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
      </lobbyists>
      <foreign_entity_issues>Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.</foreign_entity_issues>
    </ali_info>
    <ali_info>
      <issueAreaCode>TRD</issueAreaCode>
      <specific_issues>
        <description>Free Trade Agreements:
- Intellectual Property and Transparency Provisions - Free Trade Agreements
Access to Medicines Issues
Global Health Issues
India, China and Canada IP and market Access Issues
Trans-Pacific Partnership FTA
Sub-standards Medicines
Quality of Medicines
Global Intellectual Property Issues Including:
- Trade Promotion Authority
- Trans-pacific Partnership
- Trans Atlantic Trade and Investment Partnership
International Market Access and Intellectual Property Issues
Biopharmaceutical Innovation Policies</description>
      </specific_issues>
      <federal_agencies>U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, U.S. Trade Representative (USTR), Commerce - Dept of (DOC), State - Dept of (DOS), U.S. Agency for International Development (USAID)</federal_agencies>
      <lobbyists>
        <lobbyist>
          <lobbyistFirstName>Sarah</lobbyistFirstName>
          <lobbyistLastName>Haller</lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>Leo</lobbyistFirstName>
          <lobbyistLastName>Farber</lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>Jason</lobbyistFirstName>
          <lobbyistLastName>Van Pelt</lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>
          </lobbyistFirstName>
          <lobbyistLastName>
          </lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>
          </lobbyistFirstName>
          <lobbyistLastName>
          </lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>
          </lobbyistFirstName>
          <lobbyistLastName>
          </lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>
          </lobbyistFirstName>
          <lobbyistLastName>
          </lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>
          </lobbyistFirstName>
          <lobbyistLastName>
          </lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>
          </lobbyistFirstName>
          <lobbyistLastName>
          </lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
      </lobbyists>
      <foreign_entity_issues>Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.</foreign_entity_issues>
    </ali_info>
    <ali_info>
      <issueAreaCode>BUD</issueAreaCode>
      <specific_issues>
        <description>FDA Appropriations funding for Generic Drugs
Certified Importer Program (CIP)
FY 2016 Labor HHS Appropriations Bill
Reconciliation
Gx Drug Labeling
</description>
      </specific_issues>
      <federal_agencies>U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES</federal_agencies>
      <lobbyists>
        <lobbyist>
          <lobbyistFirstName>Daniel</lobbyistFirstName>
          <lobbyistLastName>Casserly</lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>Shawn</lobbyistFirstName>
          <lobbyistLastName>O'Neail</lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>Jason</lobbyistFirstName>
          <lobbyistLastName>Van Pelt</lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>Leo</lobbyistFirstName>
          <lobbyistLastName>Farber</lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>Wendy</lobbyistFirstName>
          <lobbyistLastName>Sussman</lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>
          </lobbyistFirstName>
          <lobbyistLastName>
          </lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>
          </lobbyistFirstName>
          <lobbyistLastName>
          </lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>
          </lobbyistFirstName>
          <lobbyistLastName>
          </lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>
          </lobbyistFirstName>
          <lobbyistLastName>
          </lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
      </lobbyists>
      <foreign_entity_issues>Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.</foreign_entity_issues>
    </ali_info>
    <ali_info>
      <issueAreaCode>MMM</issueAreaCode>
      <specific_issues>
        <description>Biosimilars
Medicare Part D
Drug Pricing
Part B</description>
      </specific_issues>
      <federal_agencies>U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES</federal_agencies>
      <lobbyists>
        <lobbyist>
          <lobbyistFirstName>Daniel</lobbyistFirstName>
          <lobbyistLastName>Casserly</lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>Shawn</lobbyistFirstName>
          <lobbyistLastName>O'Neail</lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>Jason</lobbyistFirstName>
          <lobbyistLastName>Van Pelt</lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>Leo</lobbyistFirstName>
          <lobbyistLastName>Farber</lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>Wendy</lobbyistFirstName>
          <lobbyistLastName>Sussman</lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>Candie</lobbyistFirstName>
          <lobbyistLastName>Phipps</lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>
          </lobbyistFirstName>
          <lobbyistLastName>
          </lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>
          </lobbyistFirstName>
          <lobbyistLastName>
          </lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>
          </lobbyistFirstName>
          <lobbyistLastName>
          </lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
      </lobbyists>
      <foreign_entity_issues>Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.</foreign_entity_issues>
    </ali_info>
    <ali_info>
      <issueAreaCode>TAX</issueAreaCode>
      <specific_issues>
        <description>ACA Pharmaceutical Industry Fee Exclusions
R&amp;D Tax Credit
Anti-Inversion Tax
H.R.3618 - Orphan Drug Fairness Act
S.1906 - Orphan Drug Fairness Act
Medical Device Tax Repeal &amp; Suspension</description>
      </specific_issues>
      <federal_agencies>U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES</federal_agencies>
      <lobbyists>
        <lobbyist>
          <lobbyistFirstName>Daniel</lobbyistFirstName>
          <lobbyistLastName>Casserly</lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>Shawn</lobbyistFirstName>
          <lobbyistLastName>O'Neail</lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>Jason</lobbyistFirstName>
          <lobbyistLastName>Van Pelt</lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>Leo</lobbyistFirstName>
          <lobbyistLastName>Farber</lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>Candie</lobbyistFirstName>
          <lobbyistLastName>Phipps</lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>
          </lobbyistFirstName>
          <lobbyistLastName>
          </lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>
          </lobbyistFirstName>
          <lobbyistLastName>
          </lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>
          </lobbyistFirstName>
          <lobbyistLastName>
          </lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>
          </lobbyistFirstName>
          <lobbyistLastName>
          </lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
      </lobbyists>
      <foreign_entity_issues>Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.</foreign_entity_issues>
    </ali_info>
    <ali_info>
      <issueAreaCode>CPT</issueAreaCode>
      <specific_issues>
        <description>HR3116 MODDERN Cures Act of 2013
S.632 STRONG Patents Act of 2015
HR.9 Innovation Act
S.1137 PATENT Act
Data Exclusivity
Trade Secrets
Intellectual Property
Biopharmaceutical Innovation Policy Issues
Biologics Data Protection Issues
Patient Litigation Reform and Issues Related to Post Grant Proceedings at PTO
S.1890 Defend Trade Secrets Act of 2016 
H.R.3326 Defend Trade Secrets Act of 2015 </description>
      </specific_issues>
      <federal_agencies>U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES</federal_agencies>
      <lobbyists>
        <lobbyist>
          <lobbyistFirstName>Daniel</lobbyistFirstName>
          <lobbyistLastName>Casserly</lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>Shawn</lobbyistFirstName>
          <lobbyistLastName>O'Neail</lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>Jason</lobbyistFirstName>
          <lobbyistLastName>Van Pelt</lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>Leo</lobbyistFirstName>
          <lobbyistLastName>Farber</lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>Candie</lobbyistFirstName>
          <lobbyistLastName>Phipps</lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>
          </lobbyistFirstName>
          <lobbyistLastName>
          </lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>
          </lobbyistFirstName>
          <lobbyistLastName>
          </lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>
          </lobbyistFirstName>
          <lobbyistLastName>
          </lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>
          </lobbyistFirstName>
          <lobbyistLastName>
          </lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
      </lobbyists>
      <foreign_entity_issues>Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.</foreign_entity_issues>
    </ali_info>
  </alis>
  <updates>
    <clientAddress>
    </clientAddress>
    <clientCity>
    </clientCity>
    <clientState>
    </clientState>
    <clientZip>
    </clientZip>
    <clientZipext>
    </clientZipext>
    <clientCountry>
    </clientCountry>
    <prinClientCity>
    </prinClientCity>
    <prinClientState>
    </prinClientState>
    <prinClientZip>
    </prinClientZip>
    <prinClientZipext>
    </prinClientZipext>
    <prinClientCountry>
    </prinClientCountry>
    <generalDescription>
    </generalDescription>
    <inactive_lobbyists>
      <inactive_lobbyist>
        <firstName>
        </firstName>
        <lastName>
        </lastName>
        <suffix>
        </suffix>
      </inactive_lobbyist>
      <inactive_lobbyist>
        <firstName>
        </firstName>
        <lastName>
        </lastName>
        <suffix>
        </suffix>
      </inactive_lobbyist>
      <inactive_lobbyist>
        <firstName>
        </firstName>
        <lastName>
        </lastName>
        <suffix>
        </suffix>
      </inactive_lobbyist>
      <inactive_lobbyist>
        <firstName>
        </firstName>
        <lastName>
        </lastName>
        <suffix>
        </suffix>
      </inactive_lobbyist>
    </inactive_lobbyists>
    <inactive_ALIs>
      <ali_Code>
      </ali_Code>
      <ali_Code>
      </ali_Code>
      <ali_Code>
      </ali_Code>
      <ali_Code>
      </ali_Code>
      <ali_Code>
      </ali_Code>
      <ali_Code>
      </ali_Code>
      <ali_Code>
      </ali_Code>
      <ali_Code>
      </ali_Code>
      <ali_Code>
      </ali_Code>
    </inactive_ALIs>
    <affiliatedUrl>
    </affiliatedUrl>
    <affiliatedOrgs>
      <affiliatedOrg>
        <affiliatedOrgName>
        </affiliatedOrgName>
        <affiliatedOrgAddress>
        </affiliatedOrgAddress>
        <affiliatedOrgCity>
        </affiliatedOrgCity>
        <affiliatedOrgState>
        </affiliatedOrgState>
        <affiliatedOrgZip>
        </affiliatedOrgZip>
        <affiliatedOrgCountry>
        </affiliatedOrgCountry>
        <affiliatedPrinOrgCity>
        </affiliatedPrinOrgCity>
        <affiliatedPrinOrgState>
        </affiliatedPrinOrgState>
        <affiliatedPrinOrgCountry>
        </affiliatedPrinOrgCountry>
      </affiliatedOrg>
      <affiliatedOrg>
        <affiliatedOrgName>
        </affiliatedOrgName>
        <affiliatedOrgAddress>
        </affiliatedOrgAddress>
        <affiliatedOrgCity>
        </affiliatedOrgCity>
        <affiliatedOrgState>
        </affiliatedOrgState>
        <affiliatedOrgZip>
        </affiliatedOrgZip>
        <affiliatedOrgCountry>
        </affiliatedOrgCountry>
        <affiliatedPrinOrgCity>
        </affiliatedPrinOrgCity>
        <affiliatedPrinOrgState>
        </affiliatedPrinOrgState>
        <affiliatedPrinOrgCountry>
        </affiliatedPrinOrgCountry>
      </affiliatedOrg>
    </affiliatedOrgs>
    <inactiveOrgs>
      <inactiveOrgName>
      </inactiveOrgName>
      <inactiveOrgName>
      </inactiveOrgName>
      <inactiveOrgName>
      </inactiveOrgName>
    </inactiveOrgs>
    <foreignEntities>
      <foreignEntity>
        <name>
        </name>
        <address>
        </address>
        <city>
        </city>
        <state>
        </state>
        <country>
        </country>
        <prinCity>
        </prinCity>
        <prinState>
        </prinState>
        <prinCountry>
        </prinCountry>
        <contribution>
        </contribution>
        <ownership_Percentage>
        </ownership_Percentage>
      </foreignEntity>
    </foreignEntities>
    <inactive_ForeignEntities>
      <inactive_ForeignEntity>
      </inactive_ForeignEntity>
      <inactive_ForeignEntity>
      </inactive_ForeignEntity>
      <inactive_ForeignEntity>
      </inactive_ForeignEntity>
      <inactive_ForeignEntity>
      </inactive_ForeignEntity>
      <inactive_ForeignEntity>
      </inactive_ForeignEntity>
      <inactive_ForeignEntity>
      </inactive_ForeignEntity>
    </inactive_ForeignEntities>
  </updates>
</LOBBYINGDISCLOSURE2>